Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health

24 Aug, 2016, 07:35 ET from Chelmsford Park SA

NEW YORK, August 24, 2016 /PRNewswire/ --

Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:

http://stock-callers.com/registration

Celgene  

Summit, New Jersey headquartered Celgene Corp.'s shares saw a slight drop of 0.17% and finished Tuesday's trading session at $114.01. A total volume of 2.30 million shares was traded. In the last month and the previous three months, the stock has advanced 5.63% and 9.94%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 7.49% and 7.35%, respectively. Moreover, shares of Celgene, which discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide, have a Relative Strength Index (RSI) of 62.61.

On July 28th, 2016, Celgene reported net product sales of $2.75 billion for Q2 2016, a 22% increase from the same period in 2015. Q2 total revenue increased 21% to $2.75 billion compared to $2.28 billion in Q2 2015. Net income for Q2 2016 based on U.S. GAAP was $598 million, or $0.75 per diluted share, compared to $356 million, or $0.43 per diluted share, in Q2 2015. Adjusted net income for Q2 2016 was $1.15 billion, or $1.44 per diluted share, compared to $1.02 billion, or $1.23 per diluted share, for the Q2 2015. Free research report on CELG is available at:

http://stock-callers.com/registration/?symbol=CELG

Sarepta Therapeutics  

On Tuesday, shares in Cambridge, Massachusetts headquartered Sarepta Therapeutics Inc. recorded a trading volume of 1.44 million shares, and ended the session 0.50% higher at $26.24. The stock has gained 10.86% in the last one month and 42.30% over the previous three months. The Company's shares are trading 18.20% above their 50-day moving average and 18.58% above their 200-day moving average. Furthermore, shares of Sarepta Therapeutics, which focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, have an RSI of 61.80. The complimentary research report on SRPT can be downloaded at:

http://stock-callers.com/registration/?symbol=SRPT

MannKind  

Shares in Valencia, California headquartered MannKind Corp. closed the day at $0.92, down 3.01%. The stock recorded a trading volume of 1.75 million shares. The Company's shares are trading 12.01% below their 50-day moving average. Additionally, shares of MannKind, which focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the US, have an RSI of 33.68.

On August 8th, 2016, Mannkind reported that net loss for Q2 2016 was $30.0 million, or $0.07 per share, based on 455.3 million weighted average shares outstanding, compared with to the net loss of $28.9 million, or $0.07 per share, based on 401.0 million weighted average shares outstanding for Q2 2015. Cash and cash equivalents at June 30th, 2016 were $63.7 million, compared to $27.7 million at March 31st, 2016. Visit us today and access our complete research report on MNKD at:

http://stock-callers.com/registration/?symbol=MNKD

Opko Health  

At the closing bell yesterday, shares in Miami, Florida headquartered Opko Health Inc. ended 2.86% lower at $9.52. A total volume of 5.38 million shares was traded, which was above their three months average volume of 3.13 million shares. The stock is trading below its 50-day moving average by 2.30%. Furthermore, shares of Opko Health, which engages in the discovery, development, and commercialization of novel and proprietary technologies in the US, Ireland, Chile, Spain, Israel, and Mexico, have an RSI of 36.75.

On August 8th, 2016, OPKO Health reported that consolidated revenues for the three months ended June 30, 2016 increased to $357.1 million from $42.4 million for the three months ended June 30th, 2015. The 2016 period includes revenue from BioReference Laboratories and EirGen which were acquired in August and May 2015, respectively. The company stated that net income for the three months ended June 30th, 2016 was $15.5 million compared with net loss of $42.8 million for the 2015 period. Cash, cash equivalents and marketable securities were $171.6 million as of June 30th, 2016. Get free access to your research report on OPK at:

http://stock-callers.com/registration/?symbol=OPK

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA